In vitro and in vivo activity of thermosensitive liposomes loaded with doxorubicin and cisplatin

References

• Carvalho Júnior AD, Vieira FP, Melo VJd, et al. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res. 2007;40(8):1149–1157.
   PubMedGoogle Scholar
• Fahimeh Z, Parvin ZM, Javid SM, et al. The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis. Expert Opin Drug Deliv. 2020;17(4):523–541.
   PubMedGoogle Scholar
• Shaloam D, Paul BT. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 5; 740:364–378.
   PubMed Web of Science ®Google Scholar
• Maswadeh M, Ahmed NA, Mohammed SA, et al. Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model. Int J Nanomed. 2015;10:2847–2855.
   PubMed Web of Science ®Google Scholar
• Ekaterina YP, Ekaterina AK, Andrei AK, et al. Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician. Front Pharmacol. 2021;12:670479.
   PubMedGoogle Scholar
• Isaac M, Byron B. Doxorubicin: an overview of the anti-cancer and chemoresistance mechanisms. Ann Clin Toxicol. 2020;3(2):1031.
   Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–782.
   PubMed Web of Science ®Google Scholar
• Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta. 1990;1029(1):91–97.
   PubMed Web of Science ®Google Scholar
• Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113(2):171–199.
   PubMed Web of Science ®Google Scholar
• Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta. 1991;1070(1):187–192.
   PubMed Web of Science ®Google Scholar
• Oku N, Namba Y, Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta. 1992;1126(3):255–260.
   PubMedGoogle Scholar
• Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987;223(1):42–46.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA. 1988;85(18):6949–6953.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992;1103(1):94–100.
   PubMedGoogle Scholar
• Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991;1066(1):29–36.
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268(1):235–237.
   PubMed Web of Science ®Google Scholar
• Senior J, Delgado C, Fisher D, et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1991;1062(1):77–82.
   PubMed Web of Science ®Google Scholar
• Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer. 2001;91(1):90–100.
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 1997;26(2–3):71–90.
   PubMedGoogle Scholar
• Gabizon A. PEGylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19(4):424–436.
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58–65.
   PubMed Web of Science ®Google Scholar
• Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84(5):1470–1478.
   PubMed Web of Science ®Google Scholar
• Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352–3356.
   PubMed Web of Science ®Google Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv Rev. 1991;6(2):181–202.
   Web of Science ®Google Scholar
• Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 1992;3(3):175–210.
   PubMed Web of Science ®Google Scholar
• Huang SK, Lee KD, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992;52(19):5135–5143.
   PubMedGoogle Scholar
• Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Influence of tumour size on uptake of 111ln-DTPA-labelled PEGylated liposomes in a human tumour xenograft model. Br J Cancer. 2000;83(5):684–688.
   PubMed Web of Science ®Google Scholar
• Dass CR, Walker TL, Burton MA, et al. Enhanced anticancer therapy mediated by specialized liposomes. J Pharm Pharmacol. 1997;49(10):972–975.
   PubMedGoogle Scholar
• Massing U. Cancer therapy with liposomal formulations of anticancer drugs. Int J Clin Pharm Ther. 1997;35:87–90.
   PubMedGoogle Scholar
• Allen TM. Liposomes: opportunities in drug delivery. Drugs. 1997;54(Supplement 4):8–14.
   PubMedGoogle Scholar
• Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia. 1999;15(5):345–370.
   PubMed Web of Science ®Google Scholar
• Karino T, Koga S, Maeta M. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn J Surg. 1988;18(3):276–283.
   PubMedGoogle Scholar
• Horsman MR, Overgaard J. Can mild hyperthermia improve tumour oxygenation? Int J Hyperthermia. 1997;13(2):141–147.
   PubMed Web of Science ®Google Scholar
• Cope D, Dewhirst M, Friedman H, et al. Enhanced delivery of a monoclonal antibody F(ab′)2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res. 1990;50(6):1803–1809.
   PubMedGoogle Scholar
• Hosono MN, Hosono M, Endo K, et al. Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J Nucl Med. 1994;35(3):504–509.
   PubMedGoogle Scholar
• Schuster J, Zalutsky M, Noska M, et al. Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. Int J Hyperthermia. 1995;11(1):59–72.
   PubMed Web of Science ®Google Scholar
• Hauck M, Coffin D, Dodge R, et al. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia. 1997;13(3):307–316.
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Watanabe T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol Jpn. 1990;40(2):79–84.
   PubMedGoogle Scholar
• Lefor A, Makohon S, Ackerman N. The effects of hyperthermia on vascular permeability in experimental liver metastasis. J Surg Oncol. 1985;28(4):297–300.
   PubMedGoogle Scholar
• Gaber MH, Wu NZ, Hong K, et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys. 1996;36(5):1177–1187.
   PubMed Web of Science ®Google Scholar
• Magin RL, Niesman MR. Temperature-dependent drug release from large unilamellar liposomes. Cancer Drug Deliv. 1984;1(2):109–117.
   PubMedGoogle Scholar
• Merlin JL. In vitro evaluation of the association of thermosensitive liposome-encapsulated doxorubicin with hyperthermia. Eur J Cancer. 1991;27(8):1031–1034.
   PubMedGoogle Scholar
• Anyarambhatla GR, Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J Liposome Res. 1999;9:499–514.
   Web of Science ®Google Scholar
• Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am. 1989;27(3):621–627.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Robins HI. Whole body hyperthermia and intraperitoneal carboplatin in residual ovarian cancer. Adv Exp Med Biol. 1990;267:197–202.
   PubMedGoogle Scholar
• Yanan L, Pengcheng X, Dongsheng H, et al. Long-circulating thermosensitive liposomes for the targeted drug delivery of oxaliplatin. Int J Nanomed. 2020;15:6721–6734.
   PubMedGoogle Scholar
• Maia ALC, e Silva ATM, César ALA, et al. Preparation and characterization of gadolinium-based thermosensitive liposomes: a potential nanosystem for selective drug delivery to cancer cells. J Drug Del Sci Technol. 2021;65:102686.
   Web of Science ®Google Scholar